A customer of Collagen Solutions has received approval from the Food and Drug Administration in the United States for a novel collagen bone graft delivery system.

The company, which has its main manufacturing base in Glasgow, said long-term client NovaBone Products was successful in the application for the Macroform system, which is designed for use in minimally invasive orthopaedic surgery.

NovaBone is said to have launched six new collagen based products into the wound care and bone graft segments in the past year.

All of those use medical grade material supplied by Collagen Solutions.

Stewart White, chief executive, said: “Once again, we see the long-term value generation that we can gain by having our collagen embedded into novel products.

“This impressive innovation by the team at NovaBone around making their collagen products easier to use ensures a commitment to growth of these products within attractive addressable markets.

“It is anticipated this regulatory approval for NovaBone will have a direct effect on revenues to Collagen Solutions.”

Last month AIM-listed Collagen Solutions was selected to be part of a European consortium looking into treatment for Parkinson’s Disease.